Bispecific antibody-drug conjugates (ADCs) targeting dual tumor-associated antigens (TAAs) offer advantages in fighting against cancer. These include

1. the ability to simultaneously target multiple tumor-driven proteins, potentially overcoming drug resistance.
2. recognize cells co-expressing both targets to increase tumor specificity and reducing off-target toxicity.
3. the combination of two targets increases the internalization and thus tumor killing.
4. Improving the enrichment and exposure of ADCs in tumor tissues for stronger and longer lasting killing of heterogeneous tumors

Advantages of Biocytogen’s novel bsADC platform

1. RenLite-derived common light chain antibodies are easy to assemble into BsAb with low mismatch rate and ideal physiochemical properties.
2. Combined with target gene knockout strategy, RenLite KO mice can generate antibodies with increased diversity, potentially against novel epitopes and with cross-species reactivity.

3. Proprietary linker/payload system BLD1102

4. Rapid generation of high-quality BsAbs/BsADCs for high-throughput in vitro and in vivo screening

Novel linker/payload system BLD1102 independently developed by Biocytogen

Briefly, BLD1102 is a new ADC platform developed by Biocytogen independently.

1. BCPT02 is a novel topoisomerase 1 inhibitor with broad-spectrum and potent tumor killing ability.
2. The uniquely designed cleavable linker has excellent hydrophilicity, making ADCs as hydrophilic as monoclonal antibodies, greatly improving ADC’s physiochemical properties.
3. BLD1102-ADCs exhibit good stability in plasma and more potent tumor killing compared to vcMMAE.
4. BLD1102 demonstrated good tolerabilities in preclinical non-human primates.

Biocytogen’s RenLite-based BsADC platform 

• BsADC developed from RenLite mice

Biocytogen's RenLite-based BsADC platform video

Off-the-shelf TAA-targeting antibodies available for flexible plug & play

20+ BsADC programs available for partnership

Posters

Festival of Biologics 2024: Generation of a TAA Antibody Library to Support the Development of Antibody-Drug Conjugates (ADC)

AACR 2024: BCG016, a first-in-class bispecific antibody-drug conjugate targeting 5T4 and MUC1, demonstrates potent preclinical anti-tumor activity

AACR 2024: BCG017, a bispecific ADC targeting PTK7 and EGFR exhibits anti-tumor efficacy in PDX models

AACR 2024: A novel EGFR×HER3-targeting bispecific antibody drug-conjugate, BCG019, demonstrates robust anti-tumor efficacy in preclinical evaluation

AACR 2024: BCG022, a novel HER3×MET bispecific antibody-drug conjugate (bsADC), demonstrates promising anti-tumor efficacy

AACR 2024: A first-in-class bispecific ADC targeting FOLR1 and MUC1 exhibits promising anti-tumor activity in a FOLR1low xenograft model

AACR 2024: BCG033, a novel bispecific antibody-drug conjugate targeting PTK7 and TROP2, demonstrates preclinical efficacy against triple-negative breast cancer and other solid tumor xenografts

SITC 2023: *DM001, a Novel TROP2xEGFR Bispecific ADC, Demonstrates Potent Tumor Growth Inhibition in Preclinical Models and Favorable Safety Profile in Cynomolgus Monkey

SITC 2023: Preclinical Evaluation of Fully Human Bispecific Antibody-drug Candidates Targeting HER3 and the Juxtamembrane Region of MUC1

SITC 2023: *DM005, an EGFR х MET Bispecific Antibody-drug Conjugate With a Novel DNA Topoisomerase I Inhibitor Payload, Showed Robust Anti-tumor Activity in Preclinical Models

SITC 2023: BSA01, a Bispecific Antibody-drug Conjugate Targeting EGFR and Membrane-bound MUC1-C, Exhibits Anti-tumor Efficacy In Vivo Efficacy Against Triple-negative Breast Cancer Xenografts

SITC 2023: BCG022: A HER3×MET Bispecific Antibody-drug Conjugate (BsADC) Targeting Key Mechanisms of Bypass Resistance in Multiple Tumor Types

SITC 2023: A Novel Bispecific Antibody-drug Conjugate Targeting PTK7 and TROP2, BCG033, Demonstrates Preclinical Efficacy Against Triple-negative Breast Cancer Xenografts

AACR 2023: A First-In-Class Anti-HER2/TROP2 Bispecific Antibody-Drug Conjugate (YH012) Exhibits Potent Anti-Tumor Efficacy

AACR 2023: YH013, a Novel Bispecific EGFR x MET Antibody-Drug Conjugate, Exhibits Potent Anti-Tumor Efficacy

AACR 2023: A Novel EGFR x MUC1 Bispecific Antibody-Drug Conjugate, BSA01, Targets MUC1 Transmembrane Cleavage Products and Improves Tumor Selectivity

AACR 2023: BCG022: A Novel Bispecific Antibody-Drug Conjugate Targeting HER3 and MET

AACR 2023: Discovery of BCG033, A Novel Anti-PTK7 x TROP2 Bispecific Antibody-Drug Conjugate with Promising Efficacy Against Triple-Negative Breast Cancer

AACR 2023: A First-In-Class Anti-TROP2/EGFR Bispecific Antibody-Drug Conjugate, DM001, Exhibits Potent Anti-Tumor Efficacy

AACR 2023: A First-In-Class Bispecific Antibody-Drug Conjugate (DM002) Targeting HER3 and the Juxtamembrane Domain of MUC1

AACR 2023: Identification of DM004, A First-In-Class Anti-5T4/MET Bispecific Antibody-Drug Conjugate

IO Summit EU 2023: YH013, a Common Light Chain Bispecific ADC Targeting EGFR and MET, Improves Preclinical Efficacy Over Its Parental Single-Targeting ADCs

AACR 2022: YH012, a Novel Bispecific Anti-HER2 and TROP2 Antibody-Drug Conjugate, Exhibits Potent Antitumor Efficacy

World ADC San Diego2022：YH013, a fully-human EGFR x MET bispecific ADC exhibits outstanding specificity and anti-tumor efficacy

PEGS-EU 2022:YH013, a fully-human EGFR x MET bispecific ADC exhibits outstanding specificity and anti-tumor eff­icacy

Webinar

April 24, 2024: Empowering Discovery and Development of Bispecific ADCs With a Common Light Chain Antibody Library and a Novel Linker/Payload